AP01

About Avalyn Pharmaceuticals

Avalyn Pharma is a private, clinical-stage biotech focused on transforming the treatment of rare lung diseases through localized inhaled drug delivery. Its pipeline features two Phase 2 assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical fixed-dose combination, AP03, aiming to improve upon the tolerability limitations of current oral therapies. Led by an experienced team with deep respiratory and corporate development expertise, the company has raised over $275 million from a syndicate of top-tier life science investors. Avalyn is positioned to address a significant unmet need in a market with established systemic therapies but substantial side-effect burdens.

About PARI Pharma

PARI Pharma is a long-established, privately-held German company that has evolved into a leading partner for inhaled drug development, leveraging its proprietary eFlow mesh nebulizer technology. It operates as a contract development and manufacturing organization (CDMO) for respiratory therapeutics, offering end-to-end support from device customization to regulatory strategy and commercial supply. With over 20 years of experience in mesh nebulization, PARI supports a robust pipeline of partner programs, including several in late-stage clinical trials, targeting complex respiratory diseases like non-CF bronchiectasis, pulmonary fibrosis, and bronchiolitis obliterans syndrome.

Therapeutic Areas